Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Methods of Identifying and Treating Patient Populations Amenable to Cancer Immunotherapy

Summary of Invention

PICI investigators at UCSF discovered a biomarker in cancer patient samples associated with a favorable response to anti-cancer immunotherapy, comprising a subpopulation of T-cells expressing two surface proteins (CD127 and PD1) at a certain level. The biomarker can be used to identify patients likely to benefit from treatment with immunotherapy.

International Publication Number

WO 2018/136784 A1 (.pdf)

International Application Filing Date